38 results about "Prostaglandin f" patented technology

A solid-phase immunoassay for 6-keto-Prostaglandin F1α, the stable hydrolysis product of prostacyclin (Prostaglandin I2) is disclosed. Prostacyclin, a potent vasodilator with anti-platelet and anti-proliferative properties is an effective treatment for primary pulmonary hypertension and pulmonary arterial hypertension associated with scleroderma and scleroderma-like syndrome. Levels of 6-keto-Prostaglandin F1α can be directly correlated with levels of prostacyclin. Therefore, 6-keto-Prostaglandin F1α has become the indicator of choice to measure prostacyclin levels. The single step immunoassay for 6-keto-Prostaglandin F1α uses the bioluminescent protein, aequorin as a label. Analyte-label conjugates were constructed by linking the carboxyl group of 6-keto-Prostaglandin F1α and lysine residues of aequorin by chemical conjugation methods. The binding properties of 6-keto-Prostaglandin F1α towards its antibody and the bioluminescent properties of aequorin are retained in the conjugate. The concentration of 6-keto-Prostaglandin F1α after extraction from plasma shows good correlation with the concentration of 6-keto-Prostaglandin F1α obtained without prior extraction of the same plasma sample. The assay allows the measurement of 6-keto-Prostaglandin F1α directly in plasma without any pre-treatment of the samples, which results in a much simpler method with a faster assay time.

The invention relates to a specific monoclonal antibody hybridoma cell strain WXX-2 of antiprostaglandin F2alpha and application thereof and belongs to the technical field of clinical detection. The specific monoclonal antibody hybridoma cell strain WXX-2 of antiprostaglandin F2alpha provided by the invention has been preserved in CGMCC with the preservation number of CGMCC No. 13087. The specific monoclonal antibody of antiprostaglandin F2alpha is secreted by the specific monoclonal antibody hybridoma cell strain WXX-2 of antiprostaglandin F2alpha. The hybridoma cell strain WXX-2 can secrete a monoclonal antibody which has relatively good specificity and relatively high sensitivity on prostaglandin F2alpha, and the 50% inhibition concentration IC50 on the prostaglandin F2alpha is 1.80 [mu]g / L. The specific monoclonal antibody can be used for specific detection of the prostaglandin F2alpha in clinical detection.

The present invention relates to a process for preparing a prostaglandin derivative and an intermediate therefor. In accordance with the present invention, the prostaglandin F (PGF) derivative can be efficiently prepared with high purity by removing the protecting group of a protected prostaglandin E (PGE) derivative obtained from conjugate addition and then stereoselectively reducing the ketone group on the cyclopentanone ring of the PGE derivative.

The invention relates to compositions which are useful for inhibiting prostaglandin F2α receptor. The compositions include, but are not limited to, linear peptides, peptide analogs, and peptidomimetics. Methods of using the compositions of the invention to treat preterm labor and dysmenorrhea are disclosed.